Abstracts tagged "pathogenesis and stem cells"

Abstract Number: 2133 • 2016 ACR/ARHP Annual Meeting
Simulation of Cartilage Damage in Osteoarthritis Using Patient-Derived Induced Pluripotent Stem Cells
Seung Min Jung¹, Yoojun Nam², Yeri Alice Rim², Yong-Beom Park¹, Seung-Ki Kwok³, Sung-Hwan Park⁴ and Ji Hyeon Ju⁵, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Osteoarthritis (OA) is a degenerative joint disease, leading to pain and functional limitation. Although OA is a most common form of musculoskeletal disease, the…
Abstract Number: 1209 • 2012 ACR/ARHP Annual Meeting
Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis
Sabine Blaschke¹, Sandra Trautmann¹, Alexander W. Beham², Burkhard Mai³, Sebastian Koelling¹, Caroline Breysach⁴, Gabriele Wolf¹, Gerhard A. Mueller¹ and Nicolai Miosge⁵, ¹Nephrology & Rheumatology, University Medical Center Goettingen, Goettingen, Germany, ²Department of Surgery, Germany, ³Vitos Orthopaedic Clinic Kassel, Kassel, Germany, ⁴Department of Surgery, Goettingen, Germany, ⁵Dept. of Prosthodontics, Goettingen, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of still unknown etiology leading to progressive cartilage and bone destruction. Proinflammatory cytokines, immunoregulatory cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].